Standard Biotools Inc (LAB) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Standard Biotools Inc   (NASDAQ: LAB)


Standard Biotools Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Standard Biotools Inc 's ROA in the third quarter of 2026?
Standard Biotools Inc achieved a return on average assets (ROA) of 21.59 % in its third quarter of 2026, this is above LAB's average return on assets of -19.4%.
Standard Biotools Inc assets over the 12 months ending in its third quarter of 2026 are valued at $616 million

ROA has improved compared to 14.32% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 44 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 407, from total ROA ranking in the second quarter of 2026 at 3889.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Total Assets Change 17.35 % 12.24 % 10.27 % 1.71 % -17.4 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 133 85 78 -75 -128
Return On Assets (TTM) 21.59 % 14.32 % 13.58 % -13.35 % -22.96 %
LAB's Total Ranking # 407 # 3889 # 3616 # 3597 # 3654
Total Assets (TTM) in million 633 625 639 568 540
Seq. Total Assets Change 1.3 % -2.19 % 12.57 % 5.21 % -3.11 %
Seq. Net Income Change - - 558.96 % - -

LAB's 5 Years Annual ROA >> Back to LAB Management Effectiveness >> Compare LAB ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 1
Sector # 45
Overall # 201

Return On Assets Statistics
High Average Low
21.56 %
-19.4 %
-51.35 %
(Sep 30 2026)   (Jun 30 2022)



  News about Standard Biotools Inc Return on Assets ROA

Standard BioTools Strengthens Leadership and Financial Strategy Amidst Third Quarter Challenges

In a move signaling its commitment to robust fiscal management and operational insight, Standard BioTools Inc. has appointed Alex Kim as Chief Financial Officer, effective November 11, 2024. This strategic decision comes against the backdrop of the company’s unveiling of its third-quarter financial results, presenting a moment of both challenge and opportunity within the competitive landscape of laboratory instrumentation.Alex Kim, a co-founder of Standard BioTools and the previous Chief Operating Officer, steps into the CFO role with nearly three decades of experience in finance and operations within the healthcare and life sciences sectors. His extensive background positions him effectively to deliver strategic oversight of the company’s finance organization, thereby ensuring that Standard BioTools capitalizes on current market dynamics while addressing any operational challenges head-on.

Revitalizing Operational Excellence: Standard BioTools Spearheads Biotech Innovations for a Sustainable Future

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
SOUTH SAN FRANCISCO, Calif., April 25, 2024 - Standard BioTools Inc. (Standard BioTools or the Company) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while supporting the execution of the Company s long-term strategic plan.
This comes as no surprise, as numerous companies across industries have been forced to reassess their operations amidst the ever-evolving market dynamics. In an effort to remain competitive, Standard BioTools has undertaken this proactive approach to optimize its operations, align with changing industry trends, and enhance profitability.



Financial Statements
Standard Biotools Inc 's Assets $ 633 million LAB's Balance sheet
Standard Biotools Inc 's Income $ 13 million Quarterly LAB's Income Statement
LAB's Income by Division See LAB's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 1.15 % 99.47 % -18.15 % 50.09 % -16.86 %
Total Assets in million 593 587 294 359 239
Y / Y Net Income Change - - - - -
Net Income in million -75 -139 -75 -190 -59
Annual Return On Assets -12.62 % -23.67 % -25.38 % -52.91 % -24.74 %

LAB's 5 Years Annual ROA >> Back to LAB Management Effectiveness >> Compare LAB ROA to its Competitors



More Return On Assets Ratios
LAB's' Return on Assets at Yahoo Finance
Laboratory Analytical Instruments Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LAB's Roa Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LAB's Competitors
Subscribers only: Roa for Standard Biotools Inc 's Suppliers
Subscribers only: Return On Assets for LAB's Customers

You may also want to know
LAB's Roi LAB's Inventory Turnover Ratio LAB's Growth Rates LAB's Dividend Comparisons
LAB's Profitability Ratios LAB's Asset Turnover Ratio LAB's Dividend Growth
LAB's Roe LAB's Valuation Ratios LAB's Financial Strength Ratios LAB's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector ROA
Alnylam Pharmaceuticals Inc   46.08 %
Ironwood Pharmaceuticals inc   42.53 %
Aurinia Pharmaceuticals Inc   40.63 %
Nurix Therapeutics Inc   38.61 %
Indivior Pharmaceuticals Inc   36.35 %
Rallybio Corporation  34.55 %
Idexx Laboratories Inc  34.05 %
Zevra Therapeutics Inc   26.33 %
Caredx Inc   25.74 %
Medpace Holdings Inc   24.47 %
Acadia Pharmaceuticals Inc   21.60 %
Standard Biotools Inc   21.56 %
Eli Lilly And Company  21.24 %
Iradimed Corporation  20.89 %
Resmed Inc   18.67 %
Alector Inc   18.37 %
Corcept Therapeutics Inc  18.09 %
Chemed Corporation  17.73 %
Halozyme Therapeutics Inc   17.26 %
Pro dex Inc   16.75 %
Denali Therapeutics Inc   16.42 %
Krystal Biotech Inc   15.48 %
West Pharmaceutical Services Inc   15.47 %
Dexcom Inc   15.47 %
Intuitive Surgical Inc   14.71 %
Vertex Pharmaceuticals Inc  14.16 %
Neurocrine Biosciences Inc   13.69 %
Illumina Inc   13.43 %
Healthcare Services Group Inc   12.79 %
Kiniksa Pharmaceuticals International Plc  12.64 %

Date modified: 2026-11-04T15:19:00+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.